Richard Lipton
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $576,745 of the $752,671 with a category attached, or 76.6%. 23 manufacturers reported payments, led by AbbVie at 26.2% of the total. Reporting peaked in 2020 at $164,936 and has fallen 67.2% since, to $54,166 in 2025. Among neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 337 payments — averaging $2233.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$197K
- Lilly USA, LLC$169K
- Pfizer$84K
- Grifols Shared Services North America, Inc.$70K
- H. Lundbeck A S$63K
- Eli Lilly$44K
- plus $125K from 17 others
Across 165 payments — averaging $5638.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$600K
- Teva Pharmaceuticals USA, Inc.$88K
- Eli Lilly$86K
- AbbVie$76K
- Pfizer$55K
- Ipsen Innovation$23K
- plus $875 from 2 others
What the payments were for
- Consulting fees$576,74577%
- Speaking & faculty fees$150,06820%
- Travel & lodging$17,0792%
- Food & beverage$5,6801%
- Education$3,1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 95 | $197,279 |
| Lilly USA, LLC | 75 | $168,840 |
| Pfizer | 33 | $84,372 |
| Grifols Shared Services North America, Inc. | 9 | $70,256 |
| H. Lundbeck A S | 33 | $62,847 |
| Eli Lilly | 30 | $43,821 |
| Amgen | 20 | $33,116 |
| Lundbeck LLC | 10 | $21,149 |
| Biohaven Pharmaceuticals, Inc. | 5 | $20,000 |
| Teva Pharmaceuticals USA, Inc. | 5 | $13,750 |
| Novartis Pharma AG | 6 | $9,951 |
| Genentech, Inc. | 2 | $5,520 |
| Scilex Pharmaceuticals Inc. | 3 | $5,454 |
| Axsome Therapeutics, Inc. | 1 | $4,875 |
| Dr.reddy's Laboratories,inc. | 1 | $3,000 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $2,000 |
| Pfizer S.A. | 1 | $2,000 |
| Pfizer Chile S.A. | 1 | $1,600 |
| Tonix Medicines, Inc. | 1 | $1,200 |
| Ipsen Innovation | 2 | $1,185 |
| Biodelivery Sciences International, Inc. | 1 | $300 |
| Promius Pharma LLC | 1 | $115 |
| Biogen | 1 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$89,825
- UBRELVY$71,412
- VYEPTI$63,692
- Gamunex-C$40,993
- BOTOX$34,589
- AIMOVIG$33,116
- Albutein$27,763
- EMGALITY$19,550
- ZAVZPRET$14,258
- AJOVY$13,728
- QULIPTA$9,389
- AMG334A_AIMOVIG_NEUROSCIENCE$7,802
- ELYXYB - CELECOXIB$3,300
- REYVOW$3,000
- AMG334_AIMOVIG_NEUROSCIENCE$2,149
- ZEMBRACE SYMTOUCH$1,200
How this compares
$752,671 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clonazepam | 13 | $52 |
Paid to pharmacies, not to this prescriber.
Other neurology in Bronx
- Michael ThorpyBronx$232K
- Rene ElkinBronx$186K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.